Market closed
BioXcel Therapeutics/BTAI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioXcel Therapeutics
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Ticker
BTAI
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
74
Website
BTAI Metrics
BasicAdvanced
$24M
Market cap
-
P/E ratio
-$3.32
EPS
0.32
Beta
-
Dividend rate
Price and volume
Market cap
$24M
Beta
0.32
52-week high
$5.62
52-week low
$0.51
Average daily volume
586K
Financial strength
Current ratio
2.352
Quick ratio
2.092
Long term debt to equity
-138.978
Total debt to equity
-139.464
Interest coverage (TTM)
-7.48%
Management effectiveness
Return on assets (TTM)
-63.62%
Return on equity (TTM)
315.13%
Valuation
Price to revenue (TTM)
7.899
Price to book
-0.32
Price to tangible book (TTM)
-0.32
Price to free cash flow (TTM)
-0.18
Growth
Revenue change (TTM)
131.50%
Earnings per share change (TTM)
-53.38%
3-year earnings per share growth (CAGR)
-6.90%
What the Analysts think about BTAI
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for BioXcel Therapeutics stock.
BTAI Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BTAI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BTAI News
AllArticlesVideos
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
GlobeNewsWire·2 weeks ago
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewsWire·1 month ago
BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for BioXcel Therapeutics stock?
BioXcel Therapeutics (BTAI) has a market cap of $24M as of October 06, 2024.
What is the P/E ratio for BioXcel Therapeutics stock?
The price to earnings (P/E) ratio for BioXcel Therapeutics (BTAI) stock is 0 as of October 06, 2024.
Does BioXcel Therapeutics stock pay dividends?
No, BioXcel Therapeutics (BTAI) stock does not pay dividends to its shareholders as of October 06, 2024.
When is the next BioXcel Therapeutics dividend payment date?
BioXcel Therapeutics (BTAI) stock does not pay dividends to its shareholders.
What is the beta indicator for BioXcel Therapeutics?
BioXcel Therapeutics (BTAI) has a beta rating of 0.32. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.